Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
THTX Stock Forecast 2025-2026
$3.15
Current Price
$144.84M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to THTX Price Targets
+28.9%
To High Target of $4.06
+25.8%
To Median Target of $3.96
+22.7%
To Low Target of $3.86
THTX Price Momentum
-1.6%
1 Week Change
+27.0%
1 Month Change
+118.8%
1 Year Change
+74.0%
Year-to-Date Change
-1.6%
From 52W High of $3.20
+181.3%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did THTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Theratechnologies is one of their latest high-conviction picks.
Latest THTX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, THTX has a bullish consensus with a median price target of $3.96 (ranging from $3.86 to $4.06). Currently trading at $3.15, the median forecast implies a 25.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
THTX Analyst Ratings
3
Buy
0
Hold
0
Sell
THTX Price Target Range
Low
$3.86
Average
$3.96
High
$4.06
Current: $3.15
Latest THTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for THTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 3, 2025 | Jones Trading | Justin Walsh | Hold | Downgrade | $0.00 |
| Oct 11, 2024 | Jones Trading | Justin Walsh | Hold | Downgrade | $0.00 |
| Jul 17, 2023 | JonesTrading | Justin Walsh | Buy | Maintains | $3.00 |
| Jul 13, 2023 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $9.00 |
| Nov 17, 2022 | Cantor Fitzgerald | Louis Chen | Overweight | Initiates | $9.00 |
| Jul 29, 2021 | Canaccord Genuity | Edward Nash | Hold | Downgrade | $3.00 |
| Apr 19, 2021 | Canaccord Genuity | Buy | Maintains | $8.00 | |
| Apr 15, 2020 | Canaccord Genuity | Edward Nash | Buy | Maintains | $11.00 |
| Dec 11, 2019 | Mackie Research | Buy | Upgrade | $0.00 |
Theratechnologies Inc. (THTX) Competitors
The following stocks are similar to Theratechnologies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Theratechnologies Inc. (THTX) Financial Data
Theratechnologies Inc. has a market capitalization of $144.84M with a P/E ratio of -18.5x. The company generates $88.67M in trailing twelve-month revenue with a -4.2% profit margin.
Revenue growth is +17.2% quarter-over-quarter, while maintaining an operating margin of +9.9% and return on equity of +32.9%.
Valuation Metrics
Market Cap
$144.84M
Enterprise Value
$154.52M
P/E Ratio
-18.5x
PEG Ratio
28.6x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+17.2%
Gross Margin
+73.5%
Operating Margin
+9.9%
Net Margin
-4.2%
EPS Growth
-19.5%
Financial Health
Cash/Price Ratio
+3.0%
Current Ratio
1.1x
Debt/Equity
-1.8x
ROE
+32.9%
ROA
+12.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Theratechnologies Inc. (THTX) Business Model
About Theratechnologies Inc.
What They Do
Develops innovative therapies for unmet medical needs.
Business Model
The company focuses on niche markets in endocrinology and oncology, generating revenue primarily through the commercialization of its specialty therapeutics such as Egrifta SV and Trogarzo. These products address specific medical conditions like HIV-associated lipodystrophy and multidrug-resistant HIV-1, representing significant unmet needs in healthcare.
Additional Information
Theratechnologies operates mainly in North American and European markets and emphasizes the use of peptide technology and biologics to enhance its therapeutic offerings. The company's commitment to research and development showcases its dedication to improving patient care and advancing biotechnology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Mr. Paul Lévesque
Country
Canada
IPO Year
N/A
Website
www.theratech.comTheratechnologies Inc. (THTX) Latest News & Analysis
Latest News
Quick Summary
Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) reported its Q2 2025 business highlights and financial results, ending May 31, 2025, with figures presented in U.S. dollars.
Why It Matters
Theratechnologies' Q2 2025 financial results and business highlights provide insights into its performance and growth potential, influencing stock valuation and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies Inc. will be acquired by CB Biotechnology for US$3.01 per share, plus contingent value rights potentially totaling US$1.19 per share, valuing the deal at US$254 million.
Why It Matters
The acquisition agreement at $3.01 per share, plus potential CVRs, signals a significant valuation for Theratechnologies, impacting stock prices and investor sentiment regarding future growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) will report its Q2 2025 financial results on July 9, 2025, covering the period ended May 31, 2025.
Why It Matters
Theratechnologies' upcoming Q2 2025 financial results could impact stock performance, providing insights into revenue growth, expenses, and overall company health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) announced the voting results from its annual shareholder meeting, held virtually on May 29, 2025.
Why It Matters
Voting results from Theratechnologies' annual meeting may indicate shareholder confidence and influence stock performance, impacting investor sentiment and future corporate decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) presented findings at ACTHIV 2025 linking EVAF to decreased muscle quality and reported successful results from tesamorelin/GLP-1 therapy.
Why It Matters
Theratechnologies' presentations on EVAF and innovative therapies could enhance its product pipeline, potentially attracting investment and boosting stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Theratechnologies is likely to accept Future Pak's $255 million offer, providing a 39%-78% premium. The company faces financial challenges and competition in its HIV franchise.
Why It Matters
Theratechnologies' potential sale at a significant premium highlights its desperate financial situation and competitive challenges, influencing investor sentiment and market valuation.
Source: Seeking Alpha
Market Sentiment:
Negative
Frequently Asked Questions About THTX Stock
What is Theratechnologies Inc.'s (THTX) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Theratechnologies Inc. (THTX) has a median price target of $3.96. The highest price target is $4.06 and the lowest is $3.86.
Is THTX stock a good investment in 2026?
According to current analyst ratings, THTX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for THTX stock?
Wall Street analysts predict THTX stock could reach $3.96 in the next 12 months. This represents a 25.8% increase from the current price of $3.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Theratechnologies Inc.'s business model?
The company focuses on niche markets in endocrinology and oncology, generating revenue primarily through the commercialization of its specialty therapeutics such as Egrifta SV and Trogarzo. These products address specific medical conditions like HIV-associated lipodystrophy and multidrug-resistant HIV-1, representing significant unmet needs in healthcare.
What is the highest forecasted price for THTX Theratechnologies Inc.?
The highest price target for THTX is $4.06 from at , which represents a 28.9% increase from the current price of $3.15.
What is the lowest forecasted price for THTX Theratechnologies Inc.?
The lowest price target for THTX is $3.86 from at , which represents a 22.7% increase from the current price of $3.15.
What is the overall THTX consensus from analysts for Theratechnologies Inc.?
The overall analyst consensus for THTX is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.96.
How accurate are THTX stock price projections?
Stock price projections, including those for Theratechnologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 6:58 PM UTC